Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MEI Pharma's annualized net income for the quarter that ended in Dec. 2024 was $-10.71 Mil. MEI Pharma's average shareholder tangible equity for the quarter that ended in Dec. 2024 was $23.49 Mil. Therefore, MEI Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was -45.59%.
The historical rank and industry rank for MEI Pharma's Return-on-Tangible-Equity or its related term are showing as below:
MEIP'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -106.9 Med: -64.04 Max: 61.68
Current: -100.3
During the past 13 years, MEI Pharma's highest Return-on-Tangible-Equity was 61.68%. The lowest was -106.90%. And the median was -64.04%.
MEIP's Return-on-Tangible-Equity is ranked worse than 72.04% of 1248
companies
in the Biotechnology industry
Industry Median: -43.835
vs MEIP: -100.30
MEI Pharma Return-on-Tangible-Equity Historical Data
The historical data trend for MEI Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MEI Pharma's Return-on-Tangible-Equity
For the Biotechnology subindustry, MEI Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's Return-on-Tangible-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MEI Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2024) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
MEI Pharma (NAS:MEIP) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MEI Pharma Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of MEI Pharma's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 